Q2 EPS Estimate for Revolution Medicines Lowered by Analyst

Revolution Medicines, Inc. (NASDAQ:RVMD) – HC Wainwright reduced their Q2 2025 earnings estimates for shares of Revolution Medicines in a research report issued to clients and investors on Wednesday, May 14th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.15) per share for the quarter, down from their previous forecast of ($1.12). HC Wainwright has a “Buy” rating and a $72.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.71) EPS, Q1 2026 earnings at ($1.26) EPS, Q2 2026 earnings at ($1.29) EPS, Q3 2026 earnings at ($1.33) EPS and Q4 2026 earnings at ($1.36) EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.01). During the same period in the prior year, the firm posted ($0.70) EPS.

Other research analysts have also recently issued reports about the company. Stifel Nicolaus lowered their price objective on Revolution Medicines from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Oppenheimer increased their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Needham & Company LLC restated a “buy” rating and issued a $57.00 price objective on shares of Revolution Medicines in a research note on Thursday, May 8th. Guggenheim decreased their target price on shares of Revolution Medicines from $87.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Wedbush reissued an “outperform” rating and set a $67.00 price target on shares of Revolution Medicines in a report on Thursday, May 8th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and a consensus target price of $67.08.

Revolution Medicines Stock Down 0.1%

Shares of NASDAQ:RVMD opened at $39.44 on Friday. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of -10.99 and a beta of 1.11. The firm’s 50 day moving average price is $37.48 and its 200 day moving average price is $43.25. Revolution Medicines has a fifty-two week low of $29.17 and a fifty-two week high of $62.40.

Insiders Place Their Bets

In other news, COO Margaret A. Horn sold 3,058 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the sale, the chief operating officer now directly owns 153,533 shares of the company’s stock, valued at $5,993,928.32. This represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jack Anders sold 1,864 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the completion of the sale, the chief financial officer now owns 115,006 shares of the company’s stock, valued at $4,489,834.24. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,660 shares of company stock valued at $650,406 over the last quarter. Insiders own 8.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. BVF Inc. IL boosted its holdings in Revolution Medicines by 19.2% during the first quarter. BVF Inc. IL now owns 4,982,384 shares of the company’s stock valued at $176,177,000 after acquiring an additional 801,205 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Revolution Medicines during the 1st quarter valued at about $42,000. ADAR1 Capital Management LLC grew its stake in shares of Revolution Medicines by 4.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 177,136 shares of the company’s stock valued at $6,264,000 after purchasing an additional 7,136 shares during the period. MPM Bioimpact LLC raised its stake in Revolution Medicines by 1.0% during the first quarter. MPM Bioimpact LLC now owns 317,083 shares of the company’s stock worth $11,212,000 after acquiring an additional 3,266 shares in the last quarter. Finally, Quarry LP bought a new position in Revolution Medicines during the 1st quarter valued at about $50,000. 94.34% of the stock is owned by institutional investors and hedge funds.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.